Rigel Pharmaceuticals Inc., of South San Francisco, said it priced its public offering of 20 million shares of common stock at $2 apiece for gross proceeds of about $40 million. Rigel granted underwriters a 30-day option to purchase up to an aggregate of 3 million additional shares, which would bring in as much as $6 million more.